Entresto
Showing 51 - 60 of 60
Systolic Heart Failure Stage D (Disorder), Mitral Regurgitation Trial in Kaohsiung (evidence-based medications vs. high-dose
Recruiting
- Systolic Heart Failure Stage D (Disorder)
- Mitral Regurgitation
- evidence-based medications vs. high-dose hydralazine + evidence-based medications
-
Kaohsiung, TaiwanE-Da hospital
Jan 4, 2022
Heart Failure, Systolic Trial (HealthReveal)
Not yet recruiting
- Heart Failure, Systolic
- HealthReveal
- (no location specified)
Aug 30, 2021
Resistant Hypertension, Blood Pressure Trial in Salvador (Sacubitril-Valsartan)
Recruiting
- Resistant Hypertension
- Blood Pressure
-
Salvador, Bahia, Brazil
- +1 more
Nov 27, 2020
Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides
Active, not recruiting
- Heart Failure
-
Milan, ItalyCentro Cardiologico Monzino
Feb 3, 2021
CHF, Hypertension Trial (Entresto, Valsartan)
Withdrawn
- Congestive Heart Failure
- Hypertension
- Entresto
- Valsartan
- (no location specified)
Feb 1, 2018
Heart Failure With Preserved Ejection Fraction Trial (Sacubitril-Valsartan)
Withdrawn
- Heart Failure With Preserved Ejection Fraction
- (no location specified)
Aug 24, 2021
Intrathoracic Impedance During Sacubitril/Valsartan Treatment
Unknown status
- Heart Failure With Reduced Ejection Fraction
- Entresto tablet
- (no location specified)
Nov 30, 2017
Ischemic Cardiomyopathy Trial in United States (Mesenchymal Stem Cells (MSC), c-kit+ cells, Placebo (Plasmalyte A))
Completed
- Ischemic Cardiomyopathy
- Mesenchymal Stem Cells (MSC)
- +2 more
-
Stanford, California
- +6 more
Mar 29, 2021
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III Trial in Nashville (Valsartan 80 mg bid,
Withdrawn
- Heart Failure NYHA Class I
- +2 more
- Valsartan 80 mg bid
- +4 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jan 9, 2018